Lisa Licitra
A5047193688- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Head and Neck Surgical Oncology
- Salivary Gland Tumors Diagnosis and Treatment
- Ear and Head Tumors
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Thyroid Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Nonmelanoma Skin Cancer Studies
- Hedgehog Signaling Pathway Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer and Skin Lesions
- Colorectal and Anal Carcinomas
- Cancer-related Molecular Pathways
- Sinusitis and nasal conditions
- Oral health in cancer treatment
- Radiopharmaceutical Chemistry and Applications
- Tumors and Oncological Cases
- Cancer-related molecular mechanisms research
- Viral-associated cancers and disorders
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
Fondazione IRCCS Istituto Nazionale dei Tumori
2016-2025
University of Milan
2015-2025
National Center for Oncological Hadrontherapy
2002-2024
European Institute of Oncology
2023-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2023
John Wiley & Sons (United States)
2021
Medscape
2021
Pfizer (United Kingdom)
2021
Takeda (United States)
2021
Infinity Pharmaceuticals (United States)
2021
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.In randomized, open-label, phase 3 trial, we assigned, in 2:1 ratio, 361 patients whose disease had progressed within 6 months platinum-based to receive nivolumab (at dose mg per kilogram body weight) every 2 weeks...
Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) phase I.We conducted double-blind, III trial comparing cabozantinib placebo 330 documented radiographic progression metastatic MTC. Patients were randomly assigned (2:1) to (140 mg per day) or placebo. The primary end point was progression-free survival...
Human papillomavirus (HPV) DNA tumors actively integrating the E6 and E7 oncogenes have a distinct biologic behavior resulting in more favorable prognosis. To which extent viral integration by itself, and/or associated wild-type (wt) TP53 status, functional p16 contribute to prognosis is unclear.To clarify how presence of high-risk (HR) -HPV, TP53, p16INK4a status interact with clinical outcome, we considered retrospective series 90 consecutive oropharyngeal cancer patients treated primarily...
Head and neck cancers, including those of the lip oral cavity, nasal paranasal sinuses, oropharynx, larynx nasopharynx represent nearly 700,000 new cases 380,000 deaths worldwide per annum, account for over 10,000 annual in United States alone. Improvement outcomes are needed patients with recurrent or metastatic squamous cell carcinoma head (HNSCC). In 2016, US Food Drug Administration (FDA) granted first immunotherapeutic approvals - anti-PD-1 immune checkpoint inhibitors nivolumab...
The expression of vascular endothelial growth factor (VEGF) is characteristic differentiated thyroid cancer and associated with aggressive tumor behavior a poor clinical outcome. Motesanib diphosphate (AMG 706) novel oral inhibitor VEGF receptors, platelet-derived growth-factor receptor, KIT.
Purpose To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated gefitinib 250 500 mg/day standard methotrexate. Patients Methods Four hundred eighty-six SCCHN were randomly assigned to oral mg/day, methotrexate 40 mg/m 2 intravenously weekly. Primary end point was overall survival, secondary points objective response rate (ORR), safety, symptom improvement, quality life (QOL). Exploratory included association efficacy...
Targeting the programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) shown evidence of additive activity several tumor types. This phase III study evaluated efficacy durvalumab (an anti-PD-L1 monoclonal antibody) or plus tremelimumab anti-CTLA-4 versus standard care (SoC) R/M HNSCC...
BackgroundBoth induction chemotherapy followed by irradiation and concurrent radiotherapy have been reported as valuable alternatives to total laryngectomy in patients with advanced larynx or hypopharynx cancer. We report results of the randomized phase 3 trial 24954 from European Organization for Research Treatment Cancer.
PURPOSE To provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy. METHODS ASCO convened an Expert Panel medical oncology, surgical radiation neuroradiology, pathology, patient advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, prospective retrospective comparative observational studies published from 2000 through 2020. Outcomes...
BackgroundThe SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog pathway inhibitor demonstrating clinical benefit advanced basal cell carcinoma (BCC)—in a patient population representative practice. Primary analysis data are presented.Patients methodsPatients with locally or metastatic BCC received oral vismodegib 150 mg/d until progressive disease, unacceptable toxicity, withdrawal. objective was...
Abstract Purpose: Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a II trial advanced medullary carcinoma (MTC). Experimental Design: Fifty-nine patients with unresectable progressive MTC per Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 within the prior 12 months received (24-mg daily, 28-day cycles) until disease progression, unmanageable toxicity, withdrawal, or death. Prior anti-VEGFR therapy was permitted. The...